The invention relates to new combinations of boron compounds and adjuvants for use in method to induce myotube formation and suppress cell mortality in a mammal in need thereof and compositions thereof.
This innovative technology helps to minimize the physiological effect of defective mRNA to provide a quality of life for patients with rare disease, as muscular dysthropies, as well as minimizing and reducing the dosages of the suitable boron compounds to non-toxic dosages, to ensure effectivity while reducing or eliminating side effects.
This innovative technology comprises new combinations of boron compounds and adjuvants and compositions thereof, suitable for use in a method to induce myotube formation and suppress cell mortality in a mammal in need thereof.
Furthermore, it is related to compositions comprising boron compounds, adjuvants and support platforms, which enhance the effect of synergistic activation of the boron cell membrane transporter (NaBC1) and adhesion receptors in cells.
The invention also refers to the aforementioned combinations and compositions for the treatment of pathophysiological condition, which affects skeletal muscle, such as dystrophy.
To be determined during further development.
Muscle regeneration
Muscular dystrophy
Aida Castellanos Paez
